Healios K.K. (OTCMKTS:HLOSF – Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totaling 417,084 shares, a drop of 17.1% from the March 15th total of 502,899 shares. Based on an average daily volume of 667 shares, the short-interest ratio is presently 625.3 days.
Healios K.K. Price Performance
Shares of Healios K.K. stock opened at $2.30 on Thursday. The firm has a fifty day moving average price of $2.33 and a 200 day moving average price of $2.68. Healios K.K. has a 1 year low of $1.90 and a 1 year high of $4.45.
Healios K.K. Company Profile
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
Featured Stories
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
